TherapeuticsMD, Inc. TXMD

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Last close 2.21 2026-09-04
Market cap $25.6M 2026-06-30 share count
52-week range 0.99 - 2.95

Valuation FY2025 figures against the last close

P/S8.5x
P/E—
P/FCF10.4x
EV/EBITDA—
Dividend yield—
Diluted EPS-0.05

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • Non-U.S.
Revenue by geography, 2 categories over 2 years. The same figures are in the table below. FY2025 United States, FY2025: 1.8M (59.3%) 59% United States Non-U.S., FY2025: 1.2M (40.7%) 41% Non-U.S. FY2024 United States, FY2024: 1.1M (63.8%) 64% Non-U.S., FY2024: 638K (36.2%) 36%
Region FY2025FY2024
United States $1.8M $1.1M
Non-U.S. $1.2M $638.0K

As the company reported it, from the “Segment Reporting - Schedule of Total Revenue (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $3.0M$1.8M$1.3M$70.0M$2.6M$64.9M$49.6M$16.1M$16.8M$19.4M
Cost of revenue ———$1.4M$1.4M$16.0M$6.3M$2.7M$2.6M$4.2M
Gross profit ——$1.3M$68.6M$1.2M$48.9M$43.3M$13.4M$14.1M$15.2M
R&D ————$7.1M$10.4M$19.8M$27.3M$33.9M$53.9M
SG&A $6.9M$6.1M$8.9M$56.7M$80.7M$77.0M$60.5M$116.0M$57.7M$51.3M
Total operating expenses $7.4M$7.9M$9.8M$67.4M$80.7M$204.4M$194.5M$143.6M$91.8M$105.4M
Operating income -$4.4M-$6.1M-$8.5M$1.2M-$79.6M-$155.5M-$151.2M-$130.2M-$77.6M-$90.3M
Interest expense ——$300.0K$200.0K$32.9M$28.6M$17.4M$4.7M——
Pre-tax income -$653.0K-$2.3M-$7.7M$1.1M-$79.3M-$183.5M-$176.1M-$132.6M-$76.9M-$89.9M
Income tax —$31.0K$43.0K———————
Net income -$569.0K-$2.2M-$10.3M$112.0M-$172.4M-$183.5M-$176.1M-$132.6M-$76.9M-$89.9M
EPS, basic -0.05-0.19-0.9912.41-21.66—————
EPS, diluted -0.05-0.19-0.9911.96-21.66-0.67-0.72-0.59-0.37-0.46
Shares, diluted (wtd. avg.) 11.6M11.5M10,4419.4M8.0M275.6M246.4M———

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $7.5M$5.1M$4.3M$49.3M$64.9M$80.5M$160.8M$161.6M$127.1M$131.5M
Receivables ————$36.2M$32.4M$24.4M$11.1M$4.3M$4.5M
Inventory ————$7.6M$8.0M$11.9M$3.3M$1.5M$1.1M
Total current assets $14.4M$12.3M$11.8M$55.4M$119.5M$128.4M$208.4M$186.8M$139.6M$139.4M
Property, plant and equipment ———$78.0K$823.0K$1.9M$2.5M$472.7K$437.1K$516.8K
Other intangibles $3.8M$4.3M$6.1M$6.9M$7.1M$41.4M$5.3M$4.1M$3.1M$2.4M
Total assets $37.7M$38.8M$43.3M$90.5M$169.5M$181.6M$266.0M$212.0M$143.2M$142.5M
Accounts payable $377.0K$258.0K$27.0K$2.2M$3.4M$21.1M$19.2M$22.7M$4.1M$7.4M
Short-term debt ————$188.3M—————
Total current liabilities $4.8M$5.2M$6.9M$46.8M$252.9M$59.2M$53.0M$41.1M$13.3M$15.0M
Long-term debt ————$0$237.7M$194.6M$73.4M——
Total liabilities $10.8M$11.5M$14.0M$55.3M$263.1M$305.6M$256.8M$114.5M$13.3M—
Retained earnings -$952.4M-$951.8M-$949.6M-$939.4M-$1.05B-$878.9M-$695.4M-$519.3M-$386.7M-$309.7M
Total equity $26.9M$27.4M$29.3M$35.1M-$93.6M-$124.0M$9.2M$97.5M$129.9M$127.5M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $2.5M$1.2M-$23.1M$9.4M-$55.1M-$159.5M-$165.7M-$106.8M-$76.2M-$69.1M
Depreciation and amortisation ——$100.0K$600.0K$400.0K$800.0K$400.0K$181.4K$141.6K$77.9K
Stock-based compensation $75.0K$264.0K$1.3M$11.6M$18.1M$10.7M$10.7M$8.7M$6.9M$17.4M
Capital expenditure ————$34.0K$207.0K$2.5M$217.0K$61.8K$396.2K
Investing cash flow ———-$355.0K-$2.2M-$1.6M-$23.9M-$21.5M-$827.1K-$1.3M
Financing cash flow ——$3.2M-$235.2M$129.6M$80.7M$188.8M$162.8M$72.6M$137.2M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-037918.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Total current liabilities
  • Inventory
  • R&D
  • Total current assets
Total current liabilities, Inventory, R&D, Total current assets by fiscal year, in US dollars The same figures are in the table below this chart. 0 100M 200M 300M Total current liabilities, FY2016: 15M Inventory, FY2016: 1.1M R&D, FY2016: 53.9M Total current assets, FY2016: 139.4M Total current liabilities, FY2017: 13.3M Inventory, FY2017: 1.5M R&D, FY2017: 33.9M Total current assets, FY2017: 139.6M Total current liabilities, FY2018: 41.1M Inventory, FY2018: 3.3M R&D, FY2018: 27.3M Total current assets, FY2018: 186.8M Total current liabilities, FY2019: 53M Inventory, FY2019: 11.9M R&D, FY2019: 19.8M Total current assets, FY2019: 208.4M Total current liabilities, FY2020: 59.2M Inventory, FY2020: 8M R&D, FY2020: 10.4M Total current assets, FY2020: 128.4M Total current liabilities, FY2021: 252.9M Inventory, FY2021: 7.6M R&D, FY2021: 7.1M Total current assets, FY2021: 119.5M Total current liabilities, FY2022: 46.8M Total current assets, FY2022: 55.4M Total current liabilities, FY2023: 6.9M Total current assets, FY2023: 11.8M Total current liabilities, FY2024: 5.2M Total current assets, FY2024: 12.3M Total current liabilities, FY2025: 4.8M Total current assets, FY2025: 14.4M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Total current liabilities $15.0M $13.3M $41.1M $53.0M $59.2M $252.9M $46.8M $6.9M $5.2M $4.8M
Inventory $1.1M $1.5M $3.3M $11.9M $8.0M $7.6M — — — —
R&D $53.9M $33.9M $27.3M $19.8M $10.4M $7.1M — — — —
Total current assets $139.4M $139.6M $186.8M $208.4M $128.4M $119.5M $55.4M $11.8M $12.3M $14.4M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
AKTX Akari Therapeutics Plc $1.79T — —
LLY ELI LILLY & Co $1.08T 50.1x 44.7%
JNJ JOHNSON & JOHNSON $663.28B 25.0x 6.0%
ONC BeOne Medicines Ltd. $529.55B 1,885.6x 40.2%
ABBV AbbVie Inc. $453.19B 108.7x 8.6%
MRK Merck & Co., Inc. $370.89B 20.6x 1.3%
ABT ABBOTT LABORATORIES $188.69B 29.1x 5.7%
PFE PFIZER INC $162.16B 20.9x -1.6%